E2F1: a magic bullet for atherosclerosis?
Dong
Chunming
C
Goldschmidt-Clermont
Pascal J
PJ
D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins / Q000378:metabolism; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; D004730:Endothelium, Vascular / Q000378:metabolism; D025461:Feedback, Physiological; D015316:Genetic Therapy; D006801:Humans; D020672:I-kappa B Proteins; D007249:Inflammation / Q000150:complications / Q000503:physiopathology; D018836:Inflammation Mediators / Q000378:metabolism; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D010766:Phosphorylation; D015398:Signal Transduction; D014157:Transcription Factors / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*
D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D050684:E2F Transcription Factors; D050687:E2F1 Transcription Factor; C493753:E2F1 protein, human; D020672:I-kappa B Proteins; D018836:Inflammation Mediators; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D014157:Transcription Factors; D000072000:NF-KappaB Inhibitor alpha